Pancreatic trials report gains

Pancreatic cancer researchers reported new signs this week that the disease may be getting more than one new treatment path at once. (nytimes.com) One approach is a targeted pill called daraxonrasib, which goes after RAS mutations that drive more than 90% of pancreatic ductal adenocarcinoma, the most common form of the disease. In a Phase 3 trial announced April 13, 2026, previously treated patients lived a median 13.2 months on daraxonrasib versus 6.7 months on standard chemotherapy. (revmed.com; pancan.org) A second daraxonrasib study moved the drug earlier, into first treatment after metastatic diagnosis. In data presented at the American Association for Cancer Research meeting in April 2026, daraxonrasib plus gemcitabine and nab-paclitaxel produced a 58% confirmed objective response rate in 40 patients, with 84% free of progression at six months. (aacrjournals.org; biopharmadive.com) Pancreatic cancer has been hard to target because the tumors are often driven by KRAS and related RAS signals that drug makers struggled for decades to block. Revolution Medicines said the Food and Drug Administration had already granted daraxonrasib breakthrough therapy designation for previously treated metastatic disease with KRAS G12 mutations, and the company plans a U.S. filing. (revmed.com; biospace.com) The other line of research uses a therapeutic mRNA vaccine, which means a custom-made shot designed from each patient’s tumor mutations after surgery. In a Phase 1 study of 16 patients, 8 mounted vaccine-linked immune responses, and 7 of those 8 were still alive four to six years after surgery, compared with 2 of 8 nonresponders. (mskcc.org; nature.com) That vaccine, autogene cevumeran, is being developed by BioNTech and Genentech and is meant to train T cells to recognize tumor-specific neoantigens, or mutation-made flags on cancer cells. Nature reported in 2025 that vaccine-induced T-cell clones in responders persisted about three years after treatment, with an average estimated lifespan of 7.7 years. (mskcc.org; nature.com) The practical consequence is that biopsy tissue now carries more weight than it did when pancreatic cancer had fewer treatment options. The New York Times reported that doctors are putting more emphasis on getting and preserving limited tumor samples so labs can run molecular testing and identify patients who might fit a RAS-targeted drug or a personalized vaccine strategy. (nytimes.com) The new results are still uneven and early in places. The first-line daraxonrasib data came from a small Phase 1/2 cohort, the vaccine findings came from 16 patients, and doctors still need larger randomized trials to show which patients benefit most and how long those gains hold up. (aacrjournals.org; mskcc.org; nature.com) For a cancer long defined by few choices, the immediate change is simpler: the tumor sample taken at diagnosis may now help determine far more than the diagnosis itself. (nytimes.com)